Form 8-K Axsome Therapeutics, For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Baird on Axsome Therapeutics (AXSM): 'Incrementally positive on regulatory updates'
December 31, 2025 1:54 PM ESTBaird analyst Joel Beatty reiterated an Outperform rating and $157.00 price target on Axsome Therapeutics (NASDAQ: AXSM).
The analyst comments "Incrementally positive on regulatory updates. Axsome announced two New Year's Eve regulatory updates, with their sNDA for AXS-05 (Auvelity) in Alzheimer's agitation... More
Leerink on Axsome Therapeutics (AXSM): 'This is very positive news'
December 31, 2025 1:20 PM ESTLeerink Partners analyst Marc Goodman reiterated an Outperform rating and $150.00 price target on Axsome Therapeutics (NASDAQ: AXSM).
The analyst comments "This is very positive news for Axsome, as Alzheimer's disease agitation (AD-A) is a key additional indication to drive... More
Axsome Therapeutics (AXSM) PT Raised to $169 at Needham
December 31, 2025 8:27 AM ESTNeedham analyst Ami Fadia raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $169.00 (from $154.00) while maintaining a Buy rating.
... More